Abstract
A new, particle-enhanced immunoturbidometric CK-MB assay that is applicable to most automated clinical analyzers has been developed. In this study, we compared the performance of the new method with an immunoinhibition-based enzymatic assay and a chemiluminescence-based immunoassay. The test results of the new method showed good run-to-run precision, good linearity, and good correlation with the chemiluminescence immunoassay. When CK anomalies were present in the serum of patients with malignant tumors, CK-MB activity was abnormally high and its correlation with the enzymatic assay was affected. When the patient samples with anomalies were excluded, the new method and CK-MB immunoinhibition method using anti-MtCK antibodies highly correlated. These results indicate that the new method, applicable to automated clinical analyzers, is useful for rapid measurement of CK-MB serum concentration.
